UK markets open in 3 hours 7 minutes
NIKKEI 225
39,030.18 +413.08 (+1.07%) HANG SENG
18,932.94 -262.66 (-1.37%) CRUDE OIL
77.17 -0.40 (-0.52%) GOLD FUTURES
2,373.20 -19.70 (-0.82%) DOW
39,671.04 -201.95 (-0.51%) Bitcoin GBP
54,453.57 -463.88 (-0.84%)
Ascletis Pharma Inc. (1672.HK)
HKSE - HKSE Delayed price. Currency in HKD
Add to watchlist
As of 11:37AM HKT. Market open.
| Previous close | 1.330 |
| Open | 1.340 |
| Bid | 1.300 x 0 |
| Ask | 1.320 x 0 |
| Day's range | 1.300 - 1.340 |
| 52-week range | 1.210 - 2.300 |
| Volume | |
| Avg. volume | 803,047 |
| Market cap | 1.317B |
| Beta (5Y monthly) | 0.64 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.150 |
| Earnings date | 25 Mar 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 3.02 |
PR NewswireAscletis Announces Strategic Decisions on FXR agonist ASC42
Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces today the strategic decisions on farnesoid X receptor (FXR) agonist ASC42.
PR NewswireAscletis Announces Poster Presentation of Phase II Study Final Results of FASN Inhibitor ASC40 for Treatment of Acne at 2024 AAD Annual Meeting
Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces the poster presentation of Phase II study final results of ASC40, a first-in-class fatty acid synthase (FASN) inhibitor for treatment of acne, at the 2024 American Academy of Dermatology (AAD) Annual Meeting in San Diego, the United States.
PR NewswireAscletis Announces Dosing of the First Patient in Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne
Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces dosing of the first patient in Phase III clinical trial of ASC40 (Denifanstat) for treatment of moderate to severe acne vulgaris at Huashan Hospital, Fudan University.
© 2024 Yahoo. All rights reserved.